

CytomX Therapeutics, Inc. Logo

CytomX to Present Overview of Precision Cancer Immunotherapies at the Jefferies Immuno-Oncology Summit

April 13, 2015

SOUTH SAN FRANCISCO, Calif., April 13, 2015 – CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced that Sean McCarthy, D. Phil., chief executive officer, will present at the upcoming Jefferies Immuno-Oncology Summit in Boston at 12:20 p.m. EDT on Wednesday, April 15. Dr. McCarthy will provide an overview of CytomX's Probody™ pipeline, including the company's precision cancer immunotherapy programs.